Omeros (OMER) said Thursday that zaltenibart, its drug candidate to treat complement 3 glomerulopathy, or C3G, was granted rare pediatric disease designation from the US Food and Drug Administration.
C3G is a rare kidney disease mainly affecting children and young adults. With no approved treatment yet, C3G often leads to end-stage renal disease within 10 years of diagnosis, according to Omeros.
The company said phase 3 clinical trials for zaltenibart in C3G are set to begin in 2025.
The FDA previously granted zaltenibart an orphan drug designation for the treatment of paroxysmal nocturnal hemoglobinuria, a rare and fatal blood disease, with phase 3 studies to be initiated later this quarter, Omeros said.
The company's shares were up nearly 2% in recent trading.
Price: 4.20, Change: +0.07, Percent Change: +1.69
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。